These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33311945)

  • 1. Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America.
    Fortes FML; Sorte NB; Mariano VD; Andrade LD; Oliveira FA; Santos MC; Dos Santos CIN; Passos CA; Pacheco MP; Surlo VC; de Almeida NP; Fontes JA; Pimentel AM; Rocha R; Santana GO
    World J Gastroenterol; 2020 Nov; 26(44):6993-7004. PubMed ID: 33311945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Latent and Active Tuberculosis Infection in Patients with Inflammatory Bowel Disease].
    Jin BC; Moon HJ; Kim SW
    Korean J Gastroenterol; 2022 Aug; 80(2):72-76. PubMed ID: 36004634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.
    Abitbol Y; Laharie D; Cosnes J; Allez M; Nancey S; Amiot A; Aubourg A; Fumery M; Altwegg R; Michetti P; Chanteloup E; Seksik P; Baudry C; Flamant M; Bouguen G; Stefanescu C; Bourrier A; Bommelaer G; Dib N; Bigard MA; Viennot S; Hébuterne X; Gornet JM; Marteau P; Bouhnik Y; Abitbol V; Nahon S;
    J Crohns Colitis; 2016 Oct; 10(10):1179-85. PubMed ID: 27402916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy.
    Greveson K; Goodhand J; Capocci S; Woodward S; Murray C; Cropley I; Hamilton M; Lipman M
    J Crohns Colitis; 2013 Jun; 7(5):412-8. PubMed ID: 23009739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
    Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea.
    Lee JY; Oh K; Hong HS; Kim K; Hong SW; Park JH; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Lee HS; Jo KW; Park SH
    BMC Gastroenterol; 2021 Oct; 21(1):390. PubMed ID: 34670529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Global Survey of Gastroenterologists' Travel Advice to Patients with Inflammatory Bowel Disease on Immunosuppressive Agents and Management of Those Visiting Tuberculosis-Endemic Areas.
    Chan W; Shim HH; Ng SC; ; Liu J; Inglis C; Greveson K; Baraty B; Haifer C; Leong RWL
    J Crohns Colitis; 2018 Nov; 12(11):1261-1269. PubMed ID: 30215692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
    Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
    World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.
    Jauregui-Amezaga A; Turon F; Ordás I; Gallego M; Feu F; Ricart E; Panés J
    J Crohns Colitis; 2013 Apr; 7(3):208-12. PubMed ID: 22677117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher risk of tuberculosis in combination therapy for inflammatory bowel disease: A nationwide population-based cohort study in South Korea.
    Choi SJ; Kim MS; Kim ES; Lee J; Lee JM; Choi HS; Keum B; Jeen YT; Lee HS; Chun HJ; Kim CD
    Medicine (Baltimore); 2020 Oct; 99(44):e22897. PubMed ID: 33126343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.
    Carpio D; Jauregui-Amezaga A; de Francisco R; de Castro L; Barreiro-de Acosta M; Mendoza JL; Mañosa M; Ollero V; Castro B; González-Conde B; Hervías D; Sierra Ausin M; Sancho Del Val L; Botella-Mateu B; Martínez-Cadilla J; Calvo M; Chaparro M; Ginard D; Guerra I; Maroto N; Calvet X; Fernández-Salgado E; Gordillo J; Rojas Feria M;
    J Crohns Colitis; 2016 Oct; 10(10):1186-93. PubMed ID: 26802085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment.
    Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
    J Gastroenterol Hepatol; 2018 Jan; 33(1):20-29. PubMed ID: 29023903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Kim JW; Shim JJ; Jang JY
    J Korean Med Sci; 2015 Feb; 30(2):173-9. PubMed ID: 25653489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management.
    Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
    J Gastroenterol Hepatol; 2018 Jan; 33(1):30-36. PubMed ID: 29024102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
    Hong SN; Kim HJ; Kim KH; Han SJ; Ahn IM; Ahn HS
    Aliment Pharmacol Ther; 2017 Jan; 45(2):253-263. PubMed ID: 27933686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region.
    Ye L; Chapman TP; Wen Z; Lin L; Qiu Y; Liu Z; Ran Z; Qian J; Wu K; Gao X; Hu P; Chen M; Travis SPL; Cao Q;
    Aliment Pharmacol Ther; 2021 Feb; 53(3):390-399. PubMed ID: 33314259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.
    Abreu C; Magro F; Santos-Antunes J; Pilão A; Rodrigues-Pinto E; Bernardes J; Bernardo A; Magina S; Vilas-Boas F; Lopes S; Macedo G; Sarmento A
    J Crohns Colitis; 2013 Nov; 7(10):e486-92. PubMed ID: 23583099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
    Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
    Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for latent tuberculosis in patients with inflammatory bowel disease under antitumor necrosis factor: data from a Portuguese center.
    Sousa M; Ladeira I; Ponte A; Fernandes C; Rodrigues A; Silva AP; Silva J; Gomes C; Afeto E; Carvalho J
    Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1099-1102. PubMed ID: 31206406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.